Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells

Area of Science:

• Endocrinology
• Molecular Biology
• Cardiovascular Research

Background:

• The farnesoid X receptor (FXR) is a nuclear receptor crucial for cholesterol metabolism.
• FXR is primarily found in the liver, kidney, adrenals, and intestine.
• FXR's role in cardiovascular disease pathogenesis is under investigation.

Purpose of the Study:

• To investigate FXR expression and function in rat pulmonary artery endothelial cells (EC).
• To determine the effect of FXR activation on endothelin-1 (ET-1) expression in EC.
• To elucidate the molecular mechanisms by which FXR influences ET-1 regulation.

Main Methods:

• Quantitative Polymerase Chain Reaction (qPCR) to assess gene expression.
• Reporter assays to evaluate promoter activity.
• Electrophoretic mobility-shift assays (EMSA) and Chromatin Immunoprecipitation (ChIP) to study protein-DNA interactions.

Main Results:

• FXR is expressed and functional in rat pulmonary artery EC, with its target gene SHP being upregulated by chenodeoxycholic acid.
• Activation of FXR in EC leads to a significant downregulation of ET-1 expression.
• FXR activation inhibits the promoter activity of the ET-1 gene and represses AP-1 response elements, suggesting interference with AP-1 signaling.

Conclusions:

• FXR is present and active in pulmonary artery EC.
• FXR activation suppresses ET-1 expression, potentially via negative interference with AP-1 signaling pathways.
• FXR represents a potential therapeutic target for modulating ET-1 levels in vascular EC and maintaining endothelial homeostasis.